1-amino-6-methyl-1,2,3,4-tetrahydroquinoline | 66556-07-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-amino-6-methyl-1,2,3,4-tetrahydroquinoline
• 英文别名: 6-methyl-3,4-dihydro-2H-[1]quinolylamine；6-Methyl-3,4-dihydro-2H-[1]chinolylamin；N-amino-6-methyl-1,2,3,4-tetrahydroquinoline；1(2H)-Quinolinamine, 3,4-dihydro-6-methyl-；6-methyl-3,4-dihydro-2H-quinolin-1-amine
• CAS: 66556-07-8
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.235
• InChiKey: FSTBMVYMVIWCKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-amino-6-methyl-1,2,3,4-tetrahydroquinoline 、 乙酰丙酸乙酯 在 盐酸 作用下， 以 溶剂黄146 为溶剂， 反应 1.0h， 以41%的产率得到ethyl (5,6-dihydro-2,8-dimethyl-4H-pyrrolo<3,2,1-ij>quinolin-1-yl)acetate
  参考文献：
  名称：

  Synthesis, Structure-Activity Relationships, and Pharmacological Evaluation of Pyrrolo[3,2,1-ij]quinoline Derivatives: Potent Histamine and Platelet Activating Factor Antagonism and 5-Lipoxygenase Inhibitory Properties. Potential Therapeutic Application in Asthma

  摘要：

  A series of pyrrolo[3,2,1-ij]quinoline derivatives was synthesized and evaluated for their in vitro and in vivo activities against histamine, platelet activating factor (PAF), and leukotrienes which are recognized to be of importance in asthma. The structure-activity relationship studies have shown that the optimum moiety on the 1-position of the pyrroloquinoline nucleus is a 2-[4-(4-methyl-2-pyridinyl)-1-piperazinyl]ethyl chain in conjunction with a methyl group on the 2-position for potent antagonism of both histamine and PAF. The introduction of substituents on the 8- and 4-positions was also investigated in order to increase the potency of 5-lipoxygenase inhibition while retaining or improving the activities against histamine and PAF. This series is exemplified by 4-n-butyl-5,6-dihydro-8-hydroxy-2-methyl-1-[2-[4-(4-methyl- 2-pyridinyl)-1-piperazinyl]ethyl]-4H-pyrrolo[3,2,1-ij]quinoline (24, KC 11404) which was found to be active against all three of the selected mediators. Compound 24 was found to be orally active in guinea pig models against the histaminic phase of antigen-induced bronchospasm and PAF-induced bronchoconstriction (ED(50) = 1.9 and 2.1 mu mol/kg, respectively). When tested against the leukotriene-dependent phase of the antigen-induced bronchoconstriction, compound 24 showed the same potency as zileuton.

  DOI：

  10.1021/jm00004a013
• 作为产物：
  描述：

  6-methyl-1-nitroso-1,2,3,4-tetrahydro-quinoline 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 1-amino-6-methyl-1,2,3,4-tetrahydroquinoline
  参考文献：
  名称：

  Synthesis, Structure-Activity Relationships, and Pharmacological Evaluation of Pyrrolo[3,2,1-ij]quinoline Derivatives: Potent Histamine and Platelet Activating Factor Antagonism and 5-Lipoxygenase Inhibitory Properties. Potential Therapeutic Application in Asthma

  摘要：

  A series of pyrrolo[3,2,1-ij]quinoline derivatives was synthesized and evaluated for their in vitro and in vivo activities against histamine, platelet activating factor (PAF), and leukotrienes which are recognized to be of importance in asthma. The structure-activity relationship studies have shown that the optimum moiety on the 1-position of the pyrroloquinoline nucleus is a 2-[4-(4-methyl-2-pyridinyl)-1-piperazinyl]ethyl chain in conjunction with a methyl group on the 2-position for potent antagonism of both histamine and PAF. The introduction of substituents on the 8- and 4-positions was also investigated in order to increase the potency of 5-lipoxygenase inhibition while retaining or improving the activities against histamine and PAF. This series is exemplified by 4-n-butyl-5,6-dihydro-8-hydroxy-2-methyl-1-[2-[4-(4-methyl- 2-pyridinyl)-1-piperazinyl]ethyl]-4H-pyrrolo[3,2,1-ij]quinoline (24, KC 11404) which was found to be active against all three of the selected mediators. Compound 24 was found to be orally active in guinea pig models against the histaminic phase of antigen-induced bronchospasm and PAF-induced bronchoconstriction (ED(50) = 1.9 and 2.1 mu mol/kg, respectively). When tested against the leukotriene-dependent phase of the antigen-induced bronchoconstriction, compound 24 showed the same potency as zileuton.

  DOI：

  10.1021/jm00004a013

文献信息

• Copper-Catalyzed Phosphorylation of <i>N</i>,<i>N</i>-Disubstituted Hydrazines: Synthesis of Multisubstituted Phosphorylhydrazides as Potential Anticancer Agents
  作者：Lvyin Zheng、Liuhuan Cai、Weijie Mei、Gongping Liu、Ling Deng、Xiaoying Zou、Xiaoya Zhuo、Yumei Zhong、Wei Guo

  DOI：10.1021/acs.joc.2c00452

  日期：2022.5.6

  An efficient copper-catalyzed aerobic oxidative cross-dehydrogenative coupling reaction for the synthesis of multisubstituted phosphorylhydrazides from N,N-disubstituted hydrazines and hydrogen phosphoryl compounds is accomplished. The reaction proceeds under mild conditions without the addition of any external oxidants and bases. This work reported here represents a direct P(═O)–N–N bond formation

  完成了一种有效的铜催化好氧氧化交叉脱氢偶联反应，用于从N，N-二取代肼和氢磷酰基化合物合成多取代磷酰肼。该反应在温和条件下进行，无需添加任何外部氧化剂和碱。本文报道的这项工作代表了直接 P(=O)-N-N 键的形成，具有操作简单、官能团耐受性好、原子和步骤经济性高等优点。此外，所选化合物对肿瘤细胞具有潜在的抑制活性，可用于筛选抗癌剂作为新化学实体的领域。
• [EN] IMMUNOSUPPRESSIVE AGENTS<br/>[FR] AGENTS IMMUNOSUPPRESSEURS
  申请人：ABBOTT LABORATORIES

  公开号：WO1994024095A1

  公开（公告）日：1994-10-27

  (EN) Compounds having a formula selected from the group consisting of (I), (a) and (III) and the respective pharmaceutically acceptable salts, esters and prodrugs thereof, wherein E is selected from the group consisting of -R14, -NR14R15, -SR14, -OR14 and -CR14R15R16 and R14, R15 and R16 are independently selected from (I) hydrogen, (II) -NR6R7, (III) substitued -(C1-to-C10alkyl), (IV) substituted -(C2-to-C10 alkenyl), (V) substituted -(C3-to-C10 alkynyl), (VI) substituted aryl, (VII) substituted heterocyclic, (VIII) substituted biaryl, (IX) substituted -aryl-heterocyclic, (X) substituted -heterocyclic-aryl, (X) substituted -Q-aryl, (XI) substituted -Q-heterocyclic, (XII) substituted -Q-biaryl, (XIII) substituted -aryl-Q-aryl', (XIV) substituted -heterocyclic-Q-heterocyclic', (XV) substituded -heterocyclic-Q-aryl, and (XVI) substituted -aryl-Q-heterocyclic. As well as pharmaceutical composition comprising such compounds and methods for the therapeutic use thereof.(FR) L'invention concerne des composés représentés par une formule choisie dans le groupe constitué de (I), (a) et (III) et leurs sels, esters et promédicaments pharmaceutiquement acceptables, dans laquelle E est choisi dans le groupe composé de -R14, -NR14, -NR14R15, -SR14, -OR14, et -CR14R15R16 et R14, R15 et R16 étant choisi parmi (I) hydrogène, (II) -NR6R7, (III) -(alkyle C1 à 10) substitué, (IV) -(alcényl C2 à C10) substitué, (V) -(alkynyle C3 à C10) substitué, (VI) aryle substitué, (VII) hétérocycle substitué, (VII) hétérocycle substitué, (VIII) biaryle substitué, (IX) aryle-hétérocylce substitué, (X) aryle-hétérocycle substitué, (X) Q-aryle substitué, (XI) Q-hétérocyle substitué, (XII) Q-biaryle substitué, (XIII) aryle-Q-aryle substitué, (XIV) hétérocycle -Q-hétérocyle substitué, (XV) hétérocycle -Q-aryle substitué et (XVI) aryle-Q-hétérocyle substitué ainsi que des compositions pharmaceutiques contenant lesdits composés et des méthodes d'utilisation thérapeutiques de ces derniers.

  这是一段医药领域的专利文本，描述了一系列化合物及其药学上可接受的盐、酯和前药，其中化合物的化学式选自(I)、(a)和(III)组成的一组中，E选自-R14、-NR14R15、-SR14、-OR14和-CR14R15R16，而R14、R15和R16分别独立地选自(I)氢、(II)-NR6R7、(III)取代的-(C1到C10烷基)、(IV)取代的-(C2到C10烯基)、(V)取代的-(C3到C10炔基)、(VI)取代的芳基、(VII)取代的杂环、(VIII)取代的双芳基、(IX)取代的-芳基-杂环、(X)取代的-杂环-芳基、(XI)取代的-Q-芳基、(XII)取代的-Q-双芳基、(XIII)取代的-芳基-Q-芳基'、(XIV)取代的-杂环-Q-杂环'、(XV)取代的-杂环-Q-芳基和(XVI)取代的-芳基-Q-杂环。此外，还描述了包含这些化合物的药物组合物以及这些化合物的治疗用途的方法。
• Metal-Free Temperature-Controlled Intermolecular [3 + 2] Annulation to Access Benzo[<i>d</i>]thiazole-2(3<i>H</i>)-thiones and Benzo[<i>d</i>]thiazol-2(3<i>H</i>)-ones
  作者：Xiaoya Zhuo、Lvyin Zheng、Xiaoying Zou、Yumei Zhong、Wei Guo

  DOI：10.1021/acs.joc.2c01060

  日期：2022.8.5

  A facile access to benzo[d]thiazole-2(3H)-thiones and benzo[d]thiazol-2(3H)-ones has been developed through a temperature-controlled intermolecular [3 + 2] annulation of N,N-disubstituted arylhydrazines with CS2 in the presence of DMSO. This protocol can obviate the prefunctionalization of the starting materials. This direct C–S/C–N bond formation reaction was performed in the absence of any external

  通过温度控制的 N,N 分子间 [3 + 2] 环化，开发了一种容易获得苯并[ d ]噻唑-2(3 H )-硫酮和苯并[ d ]噻唑-2(3 H )-酮的方法-在DMSO存在下用CS 2二取代的芳基肼。该协议可以避免起始材料的预功能化。这种直接的 C-S/C-N 键形成反应是在没有任何外部催化剂、过渡金属、碱、配体和氧化剂的情况下进行的，具有高步骤经济性。
• INDOLE DERIVATIVES AND MEDICINAL USE THEREOF
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP0805157A1

  公开（公告）日：1997-11-05

  The present invention relates to indole derivatives represented by the following compound 1 and the pharmacologically acceptable acid addition salt thereof. The compounds of the present invention were found to exhibit strong antitussive and analgesic actions as a result of pharmacological evaluation, and can be used in the pharmaceutical field as effective antitussives and analgesics.

  本发明涉及以下列化合物 1 为代表的吲哚衍生物及其药理学上可接受的酸加成盐。 药理评价发现，本发明的化合物具有很强的镇咳和镇痛作用，可作为有效的镇咳药和镇痛药用于医药领域。
• AUTOPHAGY AND PHOSPHOLIPIDOSIS PATHWAY ASSAYS
  申请人：Enzo Life Sciences, Inc.

  公开号：EP2993477A1

  公开（公告）日：2016-03-09

  Provided are assays useful for detecting and monitoring autophagy and phospholipidosis, including the progression of lysosomal storage diseases. Drugs and treatments for lysosomal storage diseases can be monitored for effectiveness in lysosomal storage disease conditions. Drug candidates and suspected toxic agents can also be screened for toxicity to cells, tissues and organs. Also provided are methods for distinguishing between phospholipidosis activators and autophagy pathway perturbation agents.

  所提供的检测方法可用于检测和监测自噬和磷脂变性，包括溶酶体贮积疾病的进展。可以监测溶酶体贮积疾病的药物和治疗方法在溶酶体贮积疾病条件下的有效性。还可以筛选候选药物和疑似毒剂对细胞、组织和器官的毒性。此外，还提供了区分磷脂酶激活剂和自噬途径扰乱剂的方法。